高级检索
当前位置: 首页 > 详情页

Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes.

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE ◇ 自然指数

机构: [1]Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430072, China [2]Institute of Model Animal, Wuhan University, Wuhan 430072, China [3]Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsha 410000, China [4]Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430072, China [5]Medical Science Research Center, Zhongnan Hospital of Wuhan University, Wuhan 430072, China [6]Department of Cardiology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan430072, China [7]Wuhan Seventh Hospital, Wuhan 430072, China [8]The Ninth Hospital of Wuhan City, Wuhan 430072, China [9]Department of General Surgery, Huanggang Central Hospital, Huanggang 438000, China [10]Department of Pulmonary and Critical Care Medicine, Renmin Hospital of Wuhan University, Wuhan 430072, China [11]Department of General Surgery, Ezhou Central Hospital, Ezhou 436000, China [12]Department of Neurology, Wuhan First Hospital/Wuhan Hospital of Traditional Chinese and Western Medicine, Wuhan 430072, China [13]Department of Urology, Wuhan Third Hospital and Tongren Hospital of Wuhan University, Wuhan 430072, China [14]Department of Stomatology, Xiantao First People’s Hospital, Xiantao 433000, China [15]The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi 445000, China [16]Department of Neurology, The First People’s Hospital of Jingmen affiliated to Hubei Minzu University, Jingmen 448000, China [17]Department of Orthopedics, The First People’s Hospital of Jingmen affiliated to Hubei Minzu University, Jingmen 448000 China [18]Department of Hepatobiliary Surgery, The First Affiliated Hospital of Changjiang University, Jingzhou 434000, China [19]Department of Hepatobiliary Surgery, Jingzhou Central Hospital, Jingzhou 434000, China [20]Department of Hepatobiliary and Pancreatic Surgery, Xianning Central Hospital, Xianning 437000, China [21]Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang 441000, China [22]Department of Hepatobiliary and Pancreatic Surgery, Suizhou Central Hospital Affiliated to Hubei Medical College, Suizhou 441300, China [23]Department of Cardiology, The First College of Clinical Medical Science, China Three Gorges University and Yichang Central People’sHospital and Institute of Cardiovascular Diseases, China Three Gorges University, Yichang 443000, China [24]Department of Gastroenterology, Wuhan Third Hospital and Tongren Hospital of Wuhan University, Wuhan 430072, China [25]Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine & Key Laboratory of Glucolipid MetabolicDisorder, Ministry of Education of China and Institute of Chinese Medicine, Guangdong Pharmaceutical University, Guangdong TCM KeyLaboratory for Metabolic Diseases, Guangzhou 510006, China [26]Department of Neonatology, Renmin Hospital of Wuhan University, Wuhan 430072, China [27]Basic Medical School, Wuhan University, Wuhan 430072, China
出处:
ISSN:

摘要:
Type 2 diabetes (T2D) is a major comorbidity of COVID-19. However, the impact of blood glucose (BG) control on the degree of required medical interventions and on mortality in patients with COVID-19 and T2D remains uncertain. Thus, we performed a retrospective, multi-centered study of 7,337 cases of COVID-19 in Hubei Province, China, among which 952 had pre-existing T2D. We found that subjects with T2D required more medical interventions and had a significantly higher mortality (7.8% versus 2.7%; adjusted hazard ratio [HR], 1.49) and multiple organ injury than the non-diabetic individuals. Further, we found that well-controlled BG (glycemic variability within 3.9 to 10.0 mmol/L) was associated with markedly lower mortality compared to individuals with poorly controlled BG (upper limit of glycemic variability exceeding 10.0 mmol/L) (adjusted HR, 0.14) during hospitalization. These findings provide clinical evidence correlating improved glycemic control with better outcomes in patients with COVID-19 and pre-existing T2D. Copyright © 2020 Elsevier Inc. All rights reserved.

基金:
语种:
高被引:
热点:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 1 区 生物
小类 | 1 区 细胞生物学 1 区 内分泌学与代谢
最新[2023]版:
大类 | 1 区 生物学
小类 | 1 区 细胞生物学 1 区 内分泌学与代谢
JCR分区:
出版当年[2018]版:
Q1 ENDOCRINOLOGY & METABOLISM Q1 CELL BIOLOGY
最新[2023]版:
Q1 CELL BIOLOGY Q1 ENDOCRINOLOGY & METABOLISM

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430072, China [2]Institute of Model Animal, Wuhan University, Wuhan 430072, China
共同第一作者:
通讯作者:
通讯机构: [1]Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430072, China [2]Institute of Model Animal, Wuhan University, Wuhan 430072, China [5]Medical Science Research Center, Zhongnan Hospital of Wuhan University, Wuhan 430072, China [27]Basic Medical School, Wuhan University, Wuhan 430072, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:21169 今日访问量:0 总访问量:1219 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)